# AstraZeneca sells commercial rights to Arimidex and Casodex

- Link: https://www.directorstalkinterviews.com/astrazeneca-divests-rights-to-arimidex-and-casodex/412801447
- Published: 2019-12-20T07:17:13+00:00
- Author: Amilia Stone

**AstraZeneca **([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced that it has agreed to sell the commercial rights to _Arimidex_ and
_Casodex_ in a number of European, African and other countries^(1) to Juvisé Pharmaceuticals.

The medicines, used primarily to treat breast and prostate cancers, have lost their
compound patent protection in these countries. AstraZeneca already divested the 
rights to both _Arimidex_ and _Casodex_ in the US in 2017.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: **“
> _Arimidex_ and _Casodex_ are important established medicines and we are pleased
> that Juvisé Pharmaceuticals will now take on the work of making sure patients 
> continue to have access to them. Today’s agreement is part of a broader strategy
> of reducing our portfolio of mature medicines to reallocate resources towards 
> developing our pipeline of new medicines.”

**Financial considerations**

As there were no closing conditions to the divestment, the agreement became effective
upon signing. Juvisé Pharmaceuticals has made an upfront payment of $181m to AstraZeneca
and may also make future sales-contingent payments of up to $17m. Income arising
from the upfront payment will be reported in AstraZeneca’s financial statements 
in the fourth quarter of 2019. Income from the upfront and any future payments will
be reported within Other Operating Income & Expense. In 2018, _Arimidex_ had sales
of $37m in the countries covered by this agreement, while _Casodex_ had sales of
$24m. The divestment does not change the Company’s financial guidance for 2019.

**About _Arimidex_**

_Arimidex_ (anastrozole) is an aromatase inhibitor, indicated primarily for the 
adjuvant treatment of postmenopausal women with hormone receptor-positive early 
breast cancer, the first-line treatment of postmenopausal women with hormone receptor-
positive or hormone receptor-unknown locally advanced or metastatic breast cancer
and the treatment of advanced breast cancer in postmenopausal women with disease
progression, following tamoxifen therapy.

**About _Casodex_**

_Casodex_ (bicalutamide) is an androgen-receptor inhibitor, indicated for use in
combination therapy with a luteinising hormone-releasing hormone analogue for the
treatment of Stage D2 metastatic carcinoma of the prostate.

**References**

_1.   For Arimidex and Casodex: Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus,
Estonia, Finland, France, France exports^(2), Germany, Greece, Ireland, Israel, 
Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Norway, Romania, Serbia,
Slovenia, Spain, Sweden, Switzerland, Algeria, Morocco, Lebanon, Tunisia, Turkey,
and French-speaking Africa (Ivory Coast, Benin, Gabon, Niger, Mauritania, Burkina
Faso, Mali, Chad, Burundi, Cameroon, Guinea, Senegal, Central African Republic, 
Togo, Djibouti, Democratic Republic of the Congo, Republic of the Congo and Madagascar).
Additionally, for Arimidex: Czech Republic, Hungary, Lithuania, Malta, Poland and
Portugal._

_2.   France exports are sales made in France, under the French entity of AstraZeneca,
for export to French DOM-TOMs (Départements d’outre-mer, Territoires d’outre-mer):
DOM-TOMs are either ‘overseas collectives’ (administrative divisions of France) 
or ‘overseas departments’ (officially part of France), and include: French Guyana,
French Polynesia, Guadeloupe, Mayotte, Martinique, New Caledonia, La Reunion, Saint-
Barthelemy, Saint-Martin, Saint-Pierre-et-Miquelon and Wallis-et-Futuna._

Share on:
